Determination of Serum and Plasma Sclerostin Concentrations by Enzyme-Linked Immunoassays

被引:58
作者
McNulty, Melissa [1 ,4 ]
Singh, Ravinder J. [5 ]
Li, Xujian [2 ,6 ]
Bergstralh, Eric J. [2 ,6 ]
Kumar, Rajiv [1 ,3 ,4 ,7 ]
机构
[1] Mayo Clin, Mayo Clin Coll Med, Div Nephrol & Hypertens, Rochester, MN 55905 USA
[2] Mayo Clin, Mayo Clin Coll Med, Div Biomed Stat & Informat, Rochester, MN 55905 USA
[3] Mayo Clin, Mayo Clin Coll Med, Div Endocrinol Diabet & Nutr, Rochester, MN 55905 USA
[4] Mayo Clin, Mayo Clin Coll Med, Dept Med, Rochester, MN 55905 USA
[5] Mayo Clin, Mayo Clin Coll Med, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[6] Mayo Clin, Mayo Clin Coll Med, Dept Hlth Sci Res, Rochester, MN 55905 USA
[7] Mayo Clin, Mayo Clin Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
BONE MORPHOGENETIC PROTEIN; ANTAGONIST; SOST;
D O I
10.1210/jc.2011-0254
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: Sclerostin alters bone formation. The precise and reproducible measurement of sclerostin concentrations in biological samples is important for assessment of metabolic bone disease. We determined sclerostin concentrations in serum and plasma using two commercially available ELISA. Methods: We measured sclerostin concentrations in serum or heparin-plasma obtained from 25 normal human subjects using two commercial ELISA available from Biomedica Medizinprodukte GmbH and TECOmedical AG. Results: With the Biomedica assay, serum sclerostin concentrations were 0.99 +/- 0.12 ng/ml (mean +/- SEM), and plasma concentrations were 1.47 +/- 0.13 ng/ml (paired t test, P < 0.001). With the TECO assay, serum sclerostin levels were 0.71 +/- 0.05 ng/ml, and plasma sclerostin concentrations were 0.80 +/- 0.06 ng/ml (paired t test, P < 0.001). Serum and plasma sclerostin concentrations were significantly different when determined by the two assays (serum, P < 0.015; plasma, P < 0.001). Recovery of added recombinant sclerostin to serum was less than expected with both Biomedica and TECO assays (P < 0.001, paired t test). Conclusions: The concentrations of sclerostin in serum and plasma are different when determined by the two assays. Serum or plasma sclerostin concentrations with current assays should be interpreted with caution. The data suggest that the same assay should be used for comparing groups of patients or patients being followed longitudinally. Standardization of sclerostin assays is required before being introduced into general clinical laboratory use. (J Clin Endocrinol Metab 96: E1159-E1162, 2011)
引用
收藏
页码:E1159 / E1162
页数:4
相关论文
共 20 条
[1]
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease [J].
Balemans, W ;
Patel, N ;
Ebeling, M ;
Van Hul, E ;
Wuyts, W ;
Lacza, C ;
Dioszegi, M ;
Dikkers, FG ;
Hildering, P ;
Willems, PJ ;
Verheij, JBGM ;
Lindpaintner, K ;
Vickery, B ;
Foernzler, D ;
Van Hul, W .
JOURNAL OF MEDICAL GENETICS, 2002, 39 (02) :91-97
[2]
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) [J].
Balemans, W ;
Ebeling, M ;
Patel, N ;
Van Hul, E ;
Olson, P ;
Dioszegi, M ;
Lacza, C ;
Wuyts, W ;
Van den Ende, J ;
Willems, P ;
Paes-Alves, AF ;
Hill, S ;
Bueno, M ;
Ramos, FJ ;
Tacconi, P ;
Dikkers, FG ;
Stratakis, C ;
Lindpaintner, K ;
Vickery, B ;
Foernzler, D ;
Van Hul, W .
HUMAN MOLECULAR GENETICS, 2001, 10 (05) :537-543
[3]
The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations [J].
Balemans, Wendy ;
Piters, Elke ;
Cleiren, Erna ;
Ai, Minrong ;
Van Wesenbeeck, Liesbeth ;
Warman, Matthew L. ;
Van Hul, Wim .
CALCIFIED TISSUE INTERNATIONAL, 2008, 82 (06) :445-453
[4]
Sclerostin-erbB-3 interactions: Modulation of erbB-3 activity by sclerostin [J].
Craig, Theodore A. ;
Kumar, Rajiv .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 402 (02) :421-424
[5]
Sclerostin binds and regulates the activity of cysteine-rich protein 61 [J].
Craig, Theodore A. ;
Bhattacharya, Resham ;
Mukhopadhyay, Debabrata ;
Kumar, Rajiv .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 392 (01) :36-40
[6]
Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women [J].
Drake, Matthew T. ;
Srinivasan, Bhuma ;
Moedder, Ulrike I. ;
Peterson, James M. ;
McCready, Louise K. ;
Riggs, B. Lawrence ;
Dwyer, Denise ;
Stolina, Marina ;
Kostenuik, Paul ;
Khosla, Sundeep .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (11) :5056-5062
[7]
Increased Sclerostin Serum Levels Associated with Bone Formation and Resorption Markers in Patients with Immobilization-Induced Bone Loss [J].
Gaudio, Agostino ;
Pennisi, Pietra ;
Bratengeier, Cornelia ;
Torrisi, Venerando ;
Lindner, Brigitte ;
Mangiafico, Roberto A. ;
Pulvirenti, Ivana ;
Hawa, Gerhard ;
Tringali, Giovanni ;
Fiore, Carmelo E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (05) :2248-2253
[8]
Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity [J].
Kusu, N ;
Laurikkala, J ;
Imanishi, M ;
Usui, H ;
Konishi, M ;
Miyake, A ;
Thesleff, I ;
Itoh, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (26) :24113-24117
[9]
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling [J].
Li, XF ;
Zhang, YZ ;
Kang, HS ;
Liu, WZ ;
Liu, P ;
Zhang, JG ;
Harris, SE ;
Wu, DQ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (20) :19883-19887
[10]
Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]